Scholarlink

Background <p>Although over 95% of patients presenting with cutaneous squamous cell carcinoma (cSCC) are cured with surgery or radiotherapy, a subset develop locally advanced disease and undergo major resection and reconstruction. This may constitute high-risk surgery with potential for prolonged recovery and no assurance of oncological, functional, or aesthetic satisfaction. Immune checkpoint inhibitors have shown promise in this setting. We report a single-center UK experience with cemiplimab for locally advanced cSCC and our surgical experience of operating on a cemiplimab patient cohort.</p> Methods <p>This retrospective cohort study included all patients treated with cemiplimab for ≥&#xa0;3 months between November 2021 and May 2025. We report the objective response rate and describe operative findings and surgical outcomes for patients who progressed on treatment. We present our early experience and discuss patient selection.</p> Results <p>In total, 25 consecutive patients were included, with a median follow-up of 16 months. The median age was 79 years (range 48–90). The objective response rate was 64%, comprising 11 complete and five partial responses. The median time to clinical response was 3 weeks. Among the 20 patients with operable disease, three (15%) underwent surgical resection for progressive disease with no surgical complications attributable to earlier cemiplimab. In total, 85% of patients avoided surgical intervention. Grade ≥&#xa0;3 toxicity occurred in 12% of patients, with one treatment discontinuation.</p> Discussion <p>Cemiplimab demonstrated robust activity in patients with advanced cSCC in this real-world population, with durable responses in long-term survivors. Salvage surgery appears feasible for patients with disease progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management

  • 期刊论文

  • 发表日期：

    2026年3月19日

查看全文
  • Olivia Sharp,
  • Francesca Ruccia,
  • Zayd Tippu,
  • Francesco Riva,
  • Francesca Castagnoli,
  • Praveena Idaikkadar,
  • Lisa Pickering,
  • Vinidh Paleri,
  • Andrew Furness,
  • Myles J. Smith,
  • Andrew J. Hayes,
  • Kieran Power

摘要

Background

Although over 95% of patients presenting with cutaneous squamous cell carcinoma (cSCC) are cured with surgery or radiotherapy, a subset develop locally advanced disease and undergo major resection and reconstruction. This may constitute high-risk surgery with potential for prolonged recovery and no assurance of oncological, functional, or aesthetic satisfaction. Immune checkpoint inhibitors have shown promise in this setting. We report a single-center UK experience with cemiplimab for locally advanced cSCC and our surgical experience of operating on a cemiplimab patient cohort.

Methods

This retrospective cohort study included all patients treated with cemiplimab for ≥ 3 months between November 2021 and May 2025. We report the objective response rate and describe operative findings and surgical outcomes for patients who progressed on treatment. We present our early experience and discuss patient selection.

Results

In total, 25 consecutive patients were included, with a median follow-up of 16 months. The median age was 79 years (range 48–90). The objective response rate was 64%, comprising 11 complete and five partial responses. The median time to clinical response was 3 weeks. Among the 20 patients with operable disease, three (15%) underwent surgical resection for progressive disease with no surgical complications attributable to earlier cemiplimab. In total, 85% of patients avoided surgical intervention. Grade ≥ 3 toxicity occurred in 12% of patients, with one treatment discontinuation.

Discussion

Cemiplimab demonstrated robust activity in patients with advanced cSCC in this real-world population, with durable responses in long-term survivors. Salvage surgery appears feasible for patients with disease progression.